Mon - Sat 09:00 am - 05:00 pm +91-96003-73840
Mon - Sat 09:00 am - 05:00 pm +91-96003-73840
Trusted By
120,000+ People
Best Hospital
Indian News
Department of Radiology
RadMagic

Growth Surveillance

Antenatal surveillance of fetal growth is an essential part of good maternity care, as lack of detection of fetal growth restriction is directly associated with stillbirth and perinatal morbidity. New algorithms and guidelines provide care pathways which rely on regular third trimester ultrasound biometry and plotting of estimated fetal weight in pregnancies considered to be at increased risk, and their implementation has increased pressures on ultrasound resources. Customised growth charts have improved the distinction between constitutional and pathological smallness and reduced unnecessary referrals.

Who should have a Fetal Anomaly Scan and why?

All women, whatever their age, have a small chance of delivering a baby with structural abnormalities that cause physical or mental limitation. Many such abnormalities can be diagnosed and ruled out with the fetal anomaly scan.

What might be seen?

Most serious abnormalities can be detected on a scan. However, it is not possible to see all problems. Some conditions such as cerebral palsy and autism will never be seen on a scan. The quality of  imaging depends on many factors, including the position of the baby and the size of the mother.

FIRST TRIMESTER SCREENING

It is important to understand that the screening test does not give a definite ‘yes’ or ‘no’ answer as to whether or not the baby does have Down syndrome. If your screening test shows a high risk that the baby has Down syndrome, you will usually be offered a diagnostic test.

These screening tests can also be utilised to get individualised chance of mother developing Pre-Eclampsia.

For endocrine problems

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

For the digestive system

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

For the ear, nose and oropharynx

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

For the respiratory system

Drug discovery and drug development are complex and expensive endeavors undertaken by pharmaceutical companies, academic scientists, and governments. As a result of this complex path from discovery to commercialization, partnering has become a standard practice for advancing drug candidates through development pipelines. Governments generally regulate what drugs can be marketed, how drugs are marketed, and in some jurisdictions,

Make an appointment

We will send you a confirmation within 24 hours. Emergency? Call 1-2554-2356-33

Although pulmonary medicine only began to evolve as a medical specialty in the 1950s, William Welch and William Osler founded the ‘parent’ organization of the American Thoracic Society, the National Association.